$357.34 Million in Sales Expected for Oak Street Health, Inc. (NYSE:OSH) This Quarter

Equities analysts forecast that Oak Street Health, Inc. (NYSE:OSH) will post sales of $357.34 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Oak Street Health’s earnings, with the lowest sales estimate coming in at $352.00 million and the highest estimate coming in at $363.10 million. Oak Street Health posted sales of $217.90 million during the same quarter last year, which would indicate a positive year over year growth rate of 64%. The firm is scheduled to issue its next earnings results on Monday, November 8th.

According to Zacks, analysts expect that Oak Street Health will report full-year sales of $1.39 billion for the current year, with estimates ranging from $1.38 billion to $1.40 billion. For the next financial year, analysts forecast that the business will report sales of $2.15 billion, with estimates ranging from $2.08 billion to $2.26 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Oak Street Health.

Oak Street Health (NYSE:OSH) last announced its quarterly earnings data on Monday, August 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.08). The company had revenue of $353.10 million for the quarter, compared to the consensus estimate of $318.09 million. Oak Street Health had a negative net margin of 27.56% and a negative return on equity of 88.34%. The company’s revenue was up 64.7% on a year-over-year basis.

OSH has been the subject of a number of analyst reports. SVB Leerink began coverage on Oak Street Health in a research note on Monday, September 27th. They set a “market perform” rating and a $51.00 price objective for the company. Cowen assumed coverage on Oak Street Health in a report on Thursday, September 9th. They set an “outperform” rating and a $61.00 target price on the stock. Canaccord Genuity dropped their target price on Oak Street Health from $67.00 to $61.00 and set a “buy” rating on the stock in a report on Wednesday, August 11th. Truist dropped their target price on Oak Street Health from $72.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Barclays initiated coverage on Oak Street Health in a report on Thursday, August 12th. They issued an “overweight” rating and a $71.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $64.25.

Oak Street Health stock traded up $2.24 during mid-day trading on Monday, hitting $41.42. The company’s stock had a trading volume of 31,215 shares, compared to its average volume of 1,497,325. The company has a 50 day moving average of $48.21 and a 200-day moving average of $55.46. The stock has a market cap of $9.98 billion and a PE ratio of -32.19. The company has a debt-to-equity ratio of 4.07, a quick ratio of 3.40 and a current ratio of 3.40. Oak Street Health has a one year low of $35.67 and a one year high of $66.31.

In other Oak Street Health news, CEO Michael T. Pykosz sold 3,473 shares of the company’s stock in a transaction dated Thursday, July 22nd. The shares were sold at an average price of $61.02, for a total transaction of $211,922.46. Following the sale, the chief executive officer now directly owns 7,898,767 shares of the company’s stock, valued at $481,982,762.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Robert Guenthner sold 5,902 shares of the company’s stock in a transaction dated Thursday, July 29th. The stock was sold at an average price of $62.88, for a total transaction of $371,117.76. Following the sale, the insider now directly owns 501,610 shares in the company, valued at $31,541,236.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 819,406 shares of company stock worth $44,010,720. Corporate insiders own 10.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. American International Group Inc. grew its position in Oak Street Health by 255.1% in the first quarter. American International Group Inc. now owns 1,580 shares of the company’s stock valued at $86,000 after purchasing an additional 1,135 shares in the last quarter. Panagora Asset Management Inc. bought a new position in Oak Street Health in the 1st quarter valued at about $117,000. Harbor Investment Advisory LLC bought a new position in Oak Street Health in the 2nd quarter valued at about $127,000. PNC Financial Services Group Inc. grew its holdings in shares of Oak Street Health by 21,572.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,384 shares of the company’s stock valued at $140,000 after purchasing an additional 2,373 shares during the last quarter. Finally, Loomis Sayles & Co. L P bought a new stake in Oak Street Health during the 1st quarter worth approximately $142,000. Institutional investors and hedge funds own 79.41% of the company’s stock.

Oak Street Health Company Profile

Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2020, it operated 79 centers in Illinois, Indiana, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, and Texas.

Further Reading: Understanding Relative Strength Index

Get a free copy of the Zacks research report on Oak Street Health (OSH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oak Street Health (NYSE:OSH)

Receive News & Ratings for Oak Street Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oak Street Health and related companies with MarketBeat.com's FREE daily email newsletter.